About BD SurePath


The BD SurePath brand includes a liquid-based Pap test that is an FDA-approved process intended for use in the screening and detection of cervical cancer, precancerous lesions and atypical cells.1 This process is a unique, proprietary cell enrichment process that eliminates nondiagnostically relevant cells and interfering substances for a clearer, easier-to-read slide. The BD SurePath Pap test standardizes collection and ensures 100% of the collected sample is sent to the laboratory for processing. No diagnostic cells are discarded in the clinic, unlike those with "rinse and swish" systems, which on average can result in the loss of 37% of the collected sample during cell transfer.

Learn more about the BD SurePath liquid-based Pap test

BD SurePath liquid-based Pap test

The BD SurePath liquid-based Pap test helps detect disease with a more quality and easily read sample than possible with conventional Pap smears and other liquid-based cytology (LBC) tests. The BD SurePath test is shown to: 

  • Increase HSIL+ detection by 64.4% compared to the conventional Pap smear2
  • Significantly reduce unsatisfactory results vs other screening methods3
  • Better tolerate samples with potentially interfering substances such as blood, mucous and inflammatory cells4

Learn more


References
  1. BD PrepStain? slide processor: direct-to-vial study population [product insert]. Franklin Lakes, NJ: Becton, Dickinson and Company; 2016.
  2. Fremont-Smith M, Marino J, Griffin B, Spencer L, Bolick D. Comparison of the Surepath liquid-based Papanicolaou smear with the conventional Papanicolaou smear in a multisite direct-to-vial study. Cancer. 102:269-279.
  3. Nyg?rd JF, Sauer T, Nyg?rd M, Skare GB, Thoresen S ?. CIN 2/3 and cervical cancer in an organised screening programme after an unsatisfactory or a normal Pap smear: a seven-year prospective study of the Norwegian population-based screening programme. J Med Screen. 2004;11(2):70-76.
  4. Nance KV. Evolution of Pap testing at a community hospital: a ten year experience. Diagn Cytopathol. 2007:35(3):148-153.

This site uses cookies. If you click accept cookies then all cookies will be written. Please review our cookies policy and configure your cookies for your experience. 

三国杀online桌面版
彩票复式计算器 黑龙江省22选5开奖结果 上海十一选五走势图手机版 山东快乐扑克三 吉林时时走势图 提供号码的时时群 36选7开奖结走势图 塞班手机捕鱼达人 易购彩app老版本下载安装 重庆时时计划博客